usph.com (USPH) Forward Price-to-Revenue Multiple

Corporate emblem and logo of US Physical Therapy Inc (USPH)

The stability of U.S. Physical Therapy (USPH) is underpinned by the implementation of ESG standards and the digitalization of its clinics. The forward price-to-sales valuation demonstrates resilience, with the metric holding around 1.80. The operational base relies on a steady patient flow, creating a reliable cash generator. However, labor shortages and stringent regulatory pricing oversight create certain risks for the business's final margins.

USPH U.S. Physical Therapy, Inc.: Future Price to Revenue in the range 07/04/2022 - 11/13/2026

USPH (usph.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes U.S. Physical Therapy, Inc.|USPH - Analyst Median Target
- market capitalization details:
Market Valuation USPH|USPH - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share U.S. Physical Therapy|USPH - Net Asset Value|Market Capitalization to Book Value Ratio usph.com|USPH - Aggregate Asset Value
- debt and solvency information:
Total Debt to Equity Ratio U.S. Physical Therapy|USPH - Long-Term Liabilities to Capital|Short-Term Debt to Equity U.S. Physical Therapy, Inc.|USPH - Company Total Debt Obligations|Debts to Book Capitalization USPH|USPH - Long-Term Debt Volume|Company Short-Term Debts U.S. Physical Therapy|Quick Ratio usph.com
- business earnings and investment ratios data:
USPH - Net Profit|Expected Profit U.S. Physical Therapy|USPH - Price to Earnings Ratio|Projected Price to Earnings U.S. Physical Therapy, Inc.|USPH - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio USPH|USPH - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) U.S. Physical Therapy|USPH - Earnings per share for the trailing year|Quarterly EPS earnings growth usph.com|USPH - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year U.S. Physical Therapy
- sales volume and revenue information:
USPH - Company Sales Revenue|Projected Sales Volume U.S. Physical Therapy, Inc.|USPH - P/S Multiple|Price-to-Projected Revenue Ratio USPH
Comprehensive company analysis:US Physical Therapy Inc USPH
Manufactured products of U.S. Physical Therapy, Inc.

For U.S. Physical Therapy (USPH), the ratio of market value to projected revenue reflects the network's ability to maintain margins amid rising personnel costs. This coefficient compares current market capitalization with expected sales volume, measuring the premium for future growth. The price action on the forward P/S chart allows for an assessment of the business valuation's adequacy relative to insurance payouts. The stability of this indicator confirms the resilience of the shareholder equity.

Analysis of competing companies

HCA Healthcare - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Tenet Healthcare Corp (THC)|FMS: Forward Price-to-Revenue Multiple|Forward Price to Sales SOLV (Solventum Health)|Encompass Health (EHC) - Price-to-Projected Revenue Ratio|Future Price to Revenue UHS (Universal Health Services, Inc.)|DVA (DaVita) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward Price-to-Revenue Multiple OPCH (Option Care Health Inc)|SGRY - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Premier, Inc. PINC|Market Cap to Expected Sales Ratio nationalvision.com (EYE)|Progyny - Forward P/S Multiple|Market Cap to Expected Sales Ratio Ardent Health ARDT|SEM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Astrana Corp|MD (Pediatrix Corp) - Forward P/S Multiple|Forward P/S Multiple pennantgroup.com|Price-to-Projected Revenue Ratio Organogenesis (ORGO)|Price-to-Projected Revenue Ratio NUTX (Nutex Health Inc)|Auna Health - Forward Price-to-Revenue Multiple|Forward Price to Sales SBC|EOLS: Forward Price-to-Revenue Multiple|chs.net - Price to Expected Revenue Ratio|SKIN: Forward P/S Multiple|MediWound - Forward Price to Sales|BTMD (Biote Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio The Joint JYNT|Price-to-Projected Revenue Ratio DocGo Inc. (DCGO)|PIII (p3hp.org) - Forward Price to Sales|Forward P/S Multiple GANX (Gain Therapeutics)|Forward P/S Multiple EUDA Health Holdings EUDA|BMGL - Price-to-Projected Revenue Ratio|Future Price to Revenue CLGN|CUPR (Cuprina Holdings (Cayman) Ltd) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio concordmedical.com (CCM)|Forward Price-to-Revenue Multiple AMS|Forward P/S Multiple MEDIROM Healthcare Group Inc.|Price-to-Projected Revenue Ratio Avalon GloboCare (ALBT)|Market Cap to Expected Sales Ratio DIH Group|Price-to-Projected Revenue Ratio Longevity Health Holdings XAGE|NIVF (newgenivf.com) - Future Price to Revenue|ATI Physical Therapy Corp - Forward P/S Multiple|Forward Price to Sales CMAX (CareMax Inc.)|KDLY (Kindly MD Corp) - Forward Price-to-Revenue Multiple|MODV: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Novo Integrated Sciences|SSY: Forward Price to Sales|Forward P/S Multiple BACK